Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04673890 · ClinicalTrials.gov registry record
Improving Cancer Survival and Reducing Treatment Variations With Protocols for Emergency Care
A clinical trial, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- 152
- Enrollment target
NCT04673890: Completed study, sponsored by University of Illinois at Chicago.
NCT04673890 is a clinical trial that has completed, run by University of Illinois at Chicago. The registered enrollment target is 152 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04673890 has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- 152 participants
- Enrollment target
Study Summary
Significant challenges and gaps remain in navigating transitions between acute care and outpatient care for many cancer survivors. This study underscores 1) implementation of Emergency Department (ED) risk-stratified treatments protocols that standardize patient care and would allow for rapid re-assessment and access to specialist care with well-coordinated cancer care plans, and 2) the significant numbers of minority cancer survivors seeking episodic care in the ED that are at increased risk of not receiving recommended post cancer treatment surveillance.
Primary Outcome
Emergency department utilization over 6 month period
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2020-08-06 |
| Est. Completion | 2022-01-15 |
What the finished NCT04673890 record still lists
NCT04673890 is an observational study that tracks outcomes without assigning an intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04673890 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04673890 about?
NCT04673890 is a clinical study titled "Improving Cancer Survival and Reducing Treatment Variations With Protocols for Emergency Care". Significant challenges and gaps remain in navigating transitions between acute care and outpatient care for many cancer survivors. This study underscores 1) implementation of Emergency Department (ED) risk-stratified treatments protocols that standardize patient care and would allow for rapid re-ass...
What is the current status of trial NCT04673890?
This trial is currently completed. The enrollment target is 152 participants. The study started on 2020-08-06. Estimated completion is 2022-01-15.
Who is sponsoring clinical trial NCT04673890?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI